VILON USAGE IN COMPLEX THERAPY OF OLDER PATIENTS WITH INOPERABLE FORMS OF CANCER
The clinical and immunological study of 30 patients with inoperable forms of carcinoma have been performed. This group included mainly patients treated with radiotherapy and new thymic immunocorrector Vilon. Patients condition before treatment was evaluated as serious. Vilon was given i.m. in dose 1 mg during 10 days twice a month with 10 day's interval. It was established considerable reduction of tumor dimension (from 30 to 80 percents) and good physical condition after one-month radiotherapy for all the patients. 2 years ago survivability was 90 percents. The patients with oesophagus and pulmonary carcinoma showed the best results. We paid attention to changes in immunity: reasonable amount decrease of leukocytes, polymorphonuclear leukocytes, lymphocytes, CD4+-cells probably resulted from radiotherapy effects. However increase of eosinophiles and CD16+-cells (NK-cells providing non-specific antitumor protection) and tendency to decrease serum concentration of IgG, TNFα and IL-8 was observed. Thus it may be perspective Vilon usage in clinical oncology and gerontology.